Travere Therapeutics Inc
NASDAQ:TVTX

Watchlist Manager
Travere Therapeutics Inc Logo
Travere Therapeutics Inc
NASDAQ:TVTX
Watchlist
Price: 36 USD 1.58% Market Closed
Market Cap: 3.2B USD

Wall Street
Price Targets

TVTX Price Targets Summary
Travere Therapeutics Inc

Wall Street analysts forecast TVTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TVTX is 42.33 USD with a low forecast of 31.31 USD and a high forecast of 51.45 USD.

Lowest
Price Target
31.31 USD
13% Downside
Average
Price Target
42.33 USD
18% Upside
Highest
Price Target
51.45 USD
43% Upside
Travere Therapeutics Inc Competitors:
Price Targets
688177
Bio-Thera Solutions Ltd
42% Upside
AVCT
Avacta Group PLC
2% Upside
300653
Yantai Zhenghai Bio-Tech Co Ltd
24% Upside
OPK
OPKO Health Inc
192% Upside
EXEL
Exelixis Inc
8% Upside
IKT
Inhibikase Therapeutics Inc
410% Upside
MRSN
Mersana Therapeutics Inc
13% Upside
RCKT
Rocket Pharmaceuticals Inc
179% Upside

Revenue
Forecast

Revenue Estimate
Travere Therapeutics Inc

The compound annual growth rate of Travere Therapeutics Inc's revenue for the next 3 years is 56%.

N/A
Past Growth
56%
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Travere Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Miss

Net Income
Forecast

Net Income Estimate
Travere Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-48%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is TVTX's stock price target?
Price Target
42.33 USD

According to Wall Street analysts, the average 1-year price target for TVTX is 42.33 USD with a low forecast of 31.31 USD and a high forecast of 51.45 USD.

What is Travere Therapeutics Inc's Revenue forecast?
Projected CAGR
56%

The compound annual growth rate of Travere Therapeutics Inc's revenue for the next 3 years is 56%.

Back to Top